X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-fedratinib-hydrochloride-35752.pdf
https://www.pharmatimes.com/news/nice_recommends_inrebic_for_rare_blood_cancer_1383756
https://www.businesswire.com/news/home/20201211005278/en/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Inrebic%C2%AE-fedratinib-for-Adult-Patients-with-Newly-Diagnosed-and-Previously-Treated-Myelofibrosis
https://www.biospace.com/article/releases/health-canada-approves-inrebic-and-174-fedratinib-first-new-treatment-in-nearly-a-decade-for-patients-living-with-myelofibrosis/
https://www.fiercepharma.com/pharma/blockbuster-balance-celgene-s-reblozyl-faces-fda-committee-for-mds
https://www.biospace.com/article/fda-action-alert-celgene-xeris-and-ardelyx/
https://www.in-pharmatechnologist.com/Article/2019/08/20/Celgene-receives-approval-for-Inrebic
http://www.pmlive.com/pharma_news/bms_buoyed_by_fda_approval_of_celgenes_myelofibrosis_drug_1297972
https://www.biospectrumasia.com/news/27/14256/fda-approves-novel-device-to-treat-idiopathic-scoliosis.html
https://www.fiercepharma.com/pharma/once-left-for-dead-celgene-s-jak-inhibitor-inrebic-scores-fda-nod-eve-takeover
https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/
https://www.biospace.com/article/fda-approves-celgene-s-7-billion-jak-inhibitor-inrebic-for-bone-marrow-cancer/
https://www.biopharmadive.com/news/celgene-wins-approval-for-drug-key-to-bristol-buyout/561100/
https://endpts.com/celgene-and-the-scientist-who-championed-fedratinibs-rise-from-sanofis-rd-graveyard-win-fda-ok/
https://www.biospace.com/article/fda-grants-celgene-s-fedratinib-priority-review-for-myelofibrosis/
Market Place
Share 
